An open-label RCT finds 24 g/day fibre cereal improves the FIB-4 fibrosis index and HbA1c in type 2 diabetes with fatty liver, without weight change. PICO summary and commentary.
Browsing: MASLD / Fatty Liver
Metabolic dysfunction-associated steatotic liver disease (formerly NAFLD/NASH), MASH, and liver-directed metabolic therapy.
In a phase 2 trial, the antisense DGAT2 inhibitor ION224 met the primary histological endpoint in MASH with fibrosis at week 51, though benefit remains preliminary and per-protocol. PICO summary and expert commentary.
An early-phase trial of the GLP-1/FGF21 dual agonist HEC88473 reported dose-proportional liver fat reduction and improved glycaemic control over 5 weeks in patients with MASLD and type 2 diabetes. PICO summary and expert commentary.
Post hoc analysis of three randomised trials showing semaglutide produces similar weight loss in MASLD and MASH regardless of type 2 diabetes status or cardiometabolic risk. PICO summary and expert commentary.
A small randomized trial finds baseline IL-1β in mononuclear cells predicts the degree of MASLD improvement after weight loss in obesity with prediabetes or early type 2 diabetes. PICO summary and expert commentary.
A small randomised trial finding that weight loss reduced IL-1β and MASLD comparably with liraglutide or lifestyle, and that baseline IL-1β predicted the extent of MASLD improvement. PICO summary and expert commentary.
A multicentre randomised trial found dapagliflozin 10 mg daily for 48 weeks improved biopsy-confirmed MASH without worsening fibrosis in more patients than placebo. PICO summary and expert commentary.
A 24-week open-label randomised trial testing pioglitazone plus empagliflozin versus monotherapy for fatty liver in type 2 diabetes. PICO summary and expert commentary.
A small secondary analysis of the EDICT randomised trial reports that initial triple therapy was associated with slower carotid intima-media thickness progression and lower liver fat than sequential add-on therapy at matched glycaemic control. PICO summary and expert commentary.
An exploratory randomised trial of an 880 kcal/day total diet replacement programme in 17 adults with compensated MASLD cirrhosis found safe weight loss and reduced liver fat, but cannot confirm efficacy. PICO summary and expert commentary.